Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"reMYND","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReMynd Commences First-in-Human Trial of ReS19-T Alzheimer\u2019s Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"reMYND","sponsor":"Korys Investments","pharmaFlowCategory":"D","amount":"$29.0 million","upfrontCash":"Undisclosed","newsHeadline":"reMYND extends Series B funding to EUR 24 million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"reMYND","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"reMYND\u2019s ReS19-T Program, Managing Calcium Homeostasis for Alzheimer\u2019s, Has Moved to MAD phase After Demonstrating Strong Safety In SAD Phase","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"reMYND","sponsor":"National Institute of Neurological Disorders","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) Begin Collaboration on Epilepsy Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by reMYND

    Menu

    reMYND

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              reMYND

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) Begin Collaboration on Epilepsy Program

              Details:

              The ReS3-T program is the result of a collaboration with KU Leuven’s Centre for Drug Design and Discovery (CD3). ReS3-T acts via a novel proprietary target, Pde6δ, to control neuronal activity.

              Lead Product(s): ReS3-T

              Therapeutic Area: Neurology Product Name: ReS3-T

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: National Institute of Neurological Disorders

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration November 04, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              reMYND

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              reMYND’s ReS19-T Program, Managing Calcium Homeostasis for Alzheimer’s, Has Moved to MAD phase After Demonstrating Strong Safety In SAD Phase

              Details:

              RES19-T has shown to produce an acute response, restoring calcium homeostasis and synaptic plasticity, aim to address the disease at its root and restore cognition in patients by reducing the cellular damage associated with memory loss.

              Lead Product(s): RES19-T

              Therapeutic Area: Neurology Product Name: RES19-T

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 21, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              reMYND

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              reMYND extends Series B funding to EUR 24 million

              Details:

              Proceeds from the fundraise will allow completion of proof-of-concept clinical trials for both the Alzheimer’s and the diabetes programs. A first-in-human trial of RES19-T for Alzheimer’s was initiated in 2020.

              Lead Product(s): RES19-T

              Therapeutic Area: Neurology Product Name: RES19-T

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Korys Investments

              Deal Size: $29.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing January 21, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              reMYND

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ReMynd Commences First-in-Human Trial of ReS19-T Alzheimer’s Program

              Details:

              RES19-T, a first-in-class small molecule, represents a novel approach to treat Alzheimer’s Disease (AD), aiming to address the disease at its root and restore cognition in patients by reducing the cellular damage associated with memory loss.

              Lead Product(s): RES19-T

              Therapeutic Area: Neurology Product Name: RES19-T

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 03, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY